CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (36,361,109)	$ (30,255,244)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,231,108	2,159,729
Share-based payments for services	1,226,690	862,796
Equity based compensation	13,685,046	10,112,968
Common stock contributed to 401(k) plan	201,099	163,340
Shares issued for settlement of clinical research costs	0	1,769,500
Gain on short-term investments	(5,621)	0
Loss on derivative instruments	694,858	349,078
Warrant inducement expense	0	805,753
Modification of warrants	24,387	5,554
(Increase)/decrease in assets:
Receivables	0	7,843
Prepaid expenses	283,964	(623,608)
Supplies used for R&D and manufacturing	(1,186,532)	(37,689)
Deposits	(240,000)	0
Increase/(decrease) in liabilities:
Accounts payable	445,981	(766,073)
Accrued expenses	363,701	406,083
Due to employees	(182,029)	(261,420)
Other liabilities	31,441	25,229
Net cash used in operating activities	(18,787,016)	(15,276,161)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net purchases of U.S. Treasury Bills	(6,145,764)	0
Purchases of property and equipment	(9,016,329)	(2,654,906)
Expenditures for patent costs	(22,641)	(39,975)
Net cash used in investing activities	(15,184,734)	(2,694,881)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	47,363,426	13,992,439
Payments of stock issuance costs	(325,034)	(752,804)
Proceeds from exercise of warrants	5,984,215	12,072,465
Proceeds from exercises of options	746,228	338,328
Proceeds from the purchase of stock by officers and directors	220,000	184,990
Proceeds from landlord funding of leasehold improvements	1,613,546	0
Payments on obligations under finance leases	(1,079,392)	(800,241)
Net cash provided by financing activities	54,522,989	25,035,177
NET INCREASE IN CASH AND CASH EQUIVALENTS	20,551,239	7,064,135
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	15,508,909	8,444,774
CASH AND CASH EQUIVALENTS, END OF YEAR	36,060,148	15,508,909
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment included in accrued expenses and accounts payable	435,412	1,184,723
Capitalizable patent costs included in accrued expenses and accounts payable	6,510	15,000
Changes to right of use assets and liabilities	551,444	399,032
Finance lease obligation included in accounts payable	855	790
Prepaid consulting services paid with issuance of common stock	363,911	164,871
Fair value of warrants liabilities on date of exercise	4,023,091	3,071,775
Financing costs included in accounts payable	0	50,499
Accrued consulting services to be paid with common stock	55,000	55,000
Cash paid for interest	$ 1,173,702	$ 1,155,026